<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04504175</url>
  </required_header>
  <id_info>
    <org_study_id>202007085</org_study_id>
    <nct_id>NCT04504175</nct_id>
  </id_info>
  <brief_title>Ketamine for Older Adults Pilot</brief_title>
  <official_title>Precision Medicine With Ketamine for Older Adults With Treatment-resistant Depression: Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study will assess the safety and feasibility of intravenous (IV) ketamine in older&#xD;
      adults with Treatment-Resistant Depression (TRD). In addition, this study will develop and&#xD;
      utilize innovative methodological approaches to demonstrate the feasibility of precision&#xD;
      medicine and mobile health approaches in depression treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants in this study will receive ketamine infusions twice a week for 4 weeks (acute&#xD;
      phase). Participants who respond or remit will continue with an additional 4 weeks of weekly&#xD;
      ketamine infusions (continuation phase). Participants will be assessed at baseline, end of&#xD;
      acute phase, and end of continuation phase for effectiveness, safety, and executive&#xD;
      functioning. Participants will be asked to complete daily surveys of their depression&#xD;
      symptoms during their participation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission from Depression</measure>
    <time_frame>4 weeks</time_frame>
    <description>Remission defined as Montgomery Asberg Depression Rating Scale score ≤10. Scale ranges from 0-60 with higher scores indicating higher depression severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Depression Severity</measure>
    <time_frame>4 weeks and 8 weeks</time_frame>
    <description>Measured by Montgomery Asberg Depression Rating Scale. Scale ranges from 0-60 with higher scores indicating higher depression severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychological Well-Being</measure>
    <time_frame>4 weeks and 8 weeks</time_frame>
    <description>Measured by NIH Toolbox Psychological Well-Being Surveys, Positive Affect and General Life Satisfaction. These two subscales are part of the Psychological Well-Being construct of the NIH Toolbox Emotion domain. For both scales, scores are presented as a t-score, with higher scores indicating higher positive affect and general life satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognition</measure>
    <time_frame>4 weeks and 8 weeks</time_frame>
    <description>Measured by NIH Toolbox</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognition</measure>
    <time_frame>4 weeks and 8 weeks</time_frame>
    <description>Measured by Miro Health Cognitive Batteries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Executive Function</measure>
    <time_frame>4 weeks and 8 weeks</time_frame>
    <description>Measured by NIH Toolbox</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Executive Function</measure>
    <time_frame>4 weeks and 8 weeks</time_frame>
    <description>Measured by Miro Health Cognitive Batteries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Suicidal Ideation</measure>
    <time_frame>4 weeks and 8 weeks</time_frame>
    <description>Measured by Scale for Suicidal Ideation. Scores range from 0-38 with higher scores indicating higher severity of suicidal ideation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <condition>Refractory Depression</condition>
  <condition>Therapy-Resistant Depression</condition>
  <condition>Late Life Depression</condition>
  <condition>Geriatric Depression</condition>
  <arm_group>
    <arm_group_label>Acute</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acute phase: ketamine infusions twice a week for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuation: for remitters/ responders, 4 weeks of weekly ketamine infusions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>ketamine will be infused using an IV infusion pump at a rate of 0.5 mg/kg of body weight over 40 minutes</description>
    <arm_group_label>Acute</arm_group_label>
    <arm_group_label>Continuation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Community-living men and women age 65 years and older;&#xD;
&#xD;
          2. Treatment-resistant depression: defined as unipolar major depressive disorder,&#xD;
             non-delusional (diagnosed by SCID-5) that persists despite ≥ 2 adequate antidepressant&#xD;
             trials of different classes in the current episode; including at least one&#xD;
             evidence-based second-line treatment in the current episode (including serotonin&#xD;
             norepinephrine reuptake inhibitors, bupropion, tricyclics, monoamine oxidase&#xD;
             inhibitors, or augmentation with an atypical antipsychotic, stimulant, bupropion,&#xD;
             lithium, or triiodothyronine&#xD;
&#xD;
          3. Persistent moderate to severe depressive symptoms determined by Patient Health&#xD;
             Questionnaire 9-item (PHQ-9)26 score ≥15 at baseline&#xD;
&#xD;
          4. Able to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Dementia per history, score &lt; 24 on the Montreal Cognitive Assessment (MoCA), or&#xD;
             determined by clinical interview with geriatric psychiatrist to have high likelihood&#xD;
             of dementia;&#xD;
&#xD;
          2. Psychotic spectrum or bipolar disorder or severe personality disorder that at the PIs&#xD;
             discretion would interfere with safe participation. Anxiety disorders are not an&#xD;
             exclusion.&#xD;
&#xD;
          3. Unstable medical conditions such that IV ketamine is not safe or tolerated or that&#xD;
             would interfere with participation in a long-term study (i.e., poorly controlled&#xD;
             hypertension, life expectancy &lt; 1 year because of terminal illness, unstable angina).&#xD;
&#xD;
          4. Baseline systolic BP &gt; 165 systolic or 100 diastolic at evaluation.&#xD;
&#xD;
          5. Current alcohol or substance use disorder or lifetime recreational ketamine use or&#xD;
             other dissociative agent (e.g., PCP).&#xD;
&#xD;
          6. Use of naltrexone, memantine, or any medication that could be considered&#xD;
             contraindicated with ketamine.&#xD;
&#xD;
          7. Taking more than 2 adequately-dosed oral antidepressants.&#xD;
&#xD;
          8. High acute risk for suicide and unable to be managed safely in the clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Lenze, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emily Lenard, MSW</last_name>
    <phone>3147475706</phone>
    <email>lenarde@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Schweiger, CCRC</last_name>
    <phone>314-362-3153</phone>
    <email>schweigj@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA Late-Life Mood, Stress, and Wellness Research Program</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yesenia Aguilar Faustino</last_name>
      <phone>310-825-2065</phone>
      <email>yafaustino@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Raquel Hernandez Sotomayor</last_name>
      <phone>310-267-5264</phone>
      <email>RHernandezSotomayor@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Helen Lavretsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine Healthy Mind Lab</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Lenard, MSW</last_name>
      <phone>314-747-5706</phone>
      <email>lenarde@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Julie Schweiger, CCRC</last_name>
      <phone>314-362-3153</phone>
      <email>schweigj@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Lenze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Adult and Late Life Depression Clinic</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esteban Ceballos</last_name>
      <phone>646-774-8670</phone>
      <email>esteban.ceballos@nyspi.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Roose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Brown, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Late-Life Depression, Evaluation, Prevention, and Treatment Program</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joelle Kincman, PhD</last_name>
      <phone>412-246-6012</phone>
      <email>scanjm2@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sunita Chickering</last_name>
      <phone>412-246-6021</phone>
      <email>chickeringsn@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jordan Karp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Ann Gebara, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6J-1H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Athina Perivolaris, RN, MN</last_name>
      <phone>416-535-8501</phone>
      <phone_ext>32897</phone_ext>
      <email>athina.perivolaris@camh.ca</email>
    </contact>
    <contact_backup>
      <last_name>Nisha Patel</last_name>
      <email>Nisha.Patel@uhnresearch.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Alastair Flint, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benoit Mulsant, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 30, 2020</study_first_submitted>
  <study_first_submitted_qc>August 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2020</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Eric Lenze</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>ketamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

